IL-12 primarily acts by eliciting robust IFN-γ secretion from NK and T cells; in multiple pre-clinical tumor models, peak IFN-γ levels in both peripheral blood and the tumor bed are detectable within 6–24 h of IL-12 administration. This evidence concerns the gene IFNG and neoplasm.